Advisory Services Network’s Protalix BioTherapeutics PLX Stock Holding History

Advisory Services Network’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$178	–	3070
2023 Q4	$178	Buy	+100	New	+$156	﹤0.01%	3744
2018 Q4	–	Sell	-100	Closed	-$1K	–	2639
2018 Q3	$1K	Hold	100	–	–	﹤0.01%	2418
2018 Q2	$0	Hold	100	–	–	﹤0.01%	2639
2018 Q1	$1K	Hold	100	–	–	﹤0.01%	2500
2017 Q4	$1K	Hold	100	–	–	﹤0.01%	2467
2017 Q3	$1K	Hold	100	–	–	﹤0.01%	2286
2017 Q2	$1K	Buy	+100	New	+$939	﹤0.01%	2229

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisory Services Network's PLX Position: Q1 2024 in Review

Advisory Services Network sold out of Protalix BioTherapeutics (PLX) in Q1 2024, closing a stake of 100 shares — an estimated $178 sold.

Advisory Services Network first reported a position in PLX in Q2 2017 and held it in 7 quarters. The position peaked at $1K in Q3 2018. 63 funds tracked by Wall St. Rank hold PLX as of Q1 2024.

Advisory Services Network reported no remaining Protalix BioTherapeutics position as of Q1 2024 after selling out during the quarter.
Advisory Services Network sold 100 Protalix BioTherapeutics shares in Q1 2024, an estimated $178.
Advisory Services Network first reported a position in Protalix BioTherapeutics in Q2 2017 and held it in 7 quarters.
Advisory Services Network's Protalix BioTherapeutics position peaked at $1K in Q3 2018.
63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2024.

Based on Advisory Services Network's 13F filing for Q1 2024, filed 6 May 2024.